Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ: TLSI )

5.255 -0.045 (-0.86%)
Streaming Delayed Price Updated: 1:03 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,873
Open 5.290
Bid (Size) 5.260 (1)
Ask (Size) 5.310 (1)
Prev. Close 5.300
Today's Range 5.200 - 5.300
52wk Range 3.500 - 10.42
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
From TriSalus Life Sciences
Via Business Wire
3 Stocks With Robust Growth Outlooks Insiders Are Buying
Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025. 
Via MarketBeat

Performance

YTD
+5.51%
+5.51%
1 Month
-5.83%
-5.83%
3 Month
+36.48%
+36.48%
6 Month
+4.88%
+4.88%
1 Year
-43.86%
-43.86%

More News

Read More
TriSalus Life Sciences Announces Key Appointments to Board of Directors
From TriSalus Life Sciences
Via Business Wire
A Look Ahead: TriSalus Life Sciences's Earnings Forecast
Via Benzinga
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
From TriSalus Life Sciences
Via Business Wire
TriSalus Announces Leadership Changes
From TriSalus Life Sciences
Via Business Wire
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
From TriSalus Life Sciences
Via Business Wire
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday
Via Benzinga
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
From TriSalus Life Sciences
Via Business Wire
Earnings Scheduled For November 14, 2024
Via Benzinga
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From TriSalus Life Sciences
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board
From TriSalus Life Sciences
Via Business Wire
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System
From TriSalus Life Sciences
Via Business Wire
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
TriSalus Reports Q2 2024 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
From TriSalus Life Sciences
Via Business Wire
Crude Oil Rises 1%; Verastem Shares Slide
Via Benzinga
Exposures Fossil Fuels
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.